Moderna, Merck mRNA cancer vaccine cuts melanoma recurrence or death risk by 42% in Phase 3
The Phase 3 results, released early at ESMO, mark the first late-stage validation of a personalized mRNA cancer vaccine, though Moderna shares fell on a sell-th
STAT · +14 outlets
Tango Therapeutics reports 82% tumor response rate for pancreatic cancer combination therapy
The early-stage data, presented at ESMO, adds momentum to targeted RAS-pathway drugs in a cancer with few effective options.
STAT · +8 outlets
Novartis remibrutinib cuts multiple sclerosis relapse rates by a third in pivotal trials
A positive late-stage result would expand Novartis's neuroscience franchise into a crowded MS market.
STAT · +6 outlets
Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
The death raises questions about the safety threshold for CAR-T therapies tested in non-cancer autoimmune conditions.
STAT · +14 outlets
Treasury proposes restrictions on U.S. investment in Chinese biotech, keeping licensing deals
The COINS Act proposal could reshape cross-border biotech dealmaking while leaving licensing arrangements intact.
STAT · +14 outlets
Most cancer drugs approved in Europe lack high clinical benefit, analysis finds
The findings add pressure on European regulators over the evidentiary bar for oncology approvals.
STAT · +14 outlets
AI drug firm Pathos raises $237M with Bristol Myers Squibb and Tempus partnership
The deal combines Tempus data, Pathos AI analysis and BMS drug development, valuing the startup at $3 billion.
STAT · +7 outlets
MDMA-assisted therapy could win FDA approval as soon as January, advocate says
An approval would mark a first for a psychedelic-assisted treatment, following a prior FDA rejection.
New York Post · +10 outlets
AstraZeneca wins FDA approval for rare kidney disease drug Ultomiris
The accelerated approval for IgA nephropathy expands AstraZeneca's complement-inhibitor franchise.
www.lifesciencefocus.com · +14 outlets
American Diabetes Association says threat preceded members' ejections but admits policies unclear
A new report adds twists to the fallout over the ADA's June convention ejections.
STAT · +1 outlets
Biohaven's previously rejected rare disease drug troriluzole gets fresh FDA review
The FDA's acceptance of a new submission offers a potential turnaround for the spinocerebellar ataxia treatment.
Biopharmadive · +3 outlets
Arbutus Biopharma says FDA lifts clinical hold on oral PD-L1 inhibitor AB-101
The hold's removal clears the company to resume clinical development of the oral checkpoint inhibitor.
Mugglehead Investment Magazine · +9 outlets
Protein degrader developer Lycia Therapeutics prices $318M IPO
The upsized offering will fund protein-degrading medicines for allergic and autoimmune conditions.
Biopharmadive · +3 outlets
Star Therapeutics adds $200M after spinout successes
Following exits for Electra and Vega, Star is funding a search for a new drug prospect.
Biopharmadive · +3 outlets
BioNTech partner ImPact reports early Phase 1 padeliporfin data in pancreatic cancer
Seven previously unresectable patients underwent surgical resection after treatment, an encouraging early signal.
GlobeNewswire · +2 outlets
New bipartisan bill aims to speed clinical trials for rare disease treatments
The legislation targets regulatory friction that slows development of therapies for small patient populations.
CNBC · +12 outlets
GLP-1 compounder issues recall for copycat Zepbound
The recall adds to safety concerns over compounded weight loss drugs as Lilly and Novo press legal challenges.
Biopharmadive · +1 outlets
Medicaid work requirements stir anxiety as states and a Boston judge weigh implementation
State Medicaid directors met behind closed doors as a court challenge proceeds over the sweeping changes.
STAT · +1 outlets